Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752678 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KCNA5KCNH2TP53P2RX7 | |
| SCHEMBL3754255 | 0.81 | GAA (0.62) | ALDH1A1NPSR1LMNATDP1MAPT | |
| SCHEMBL3752503 | 0.78 | ALDH1A1 (0.81) | ALDH1A1NPSR1MCHR1LMNATDP1 | |
| SCHEMBL3746135 | 0.76 | ALDH1A1 (0.65) | ALDH1A1NPSR1MCHR1LMNAKCNA5 | |
| SCHEMBL28889859 | 0.73 | ALDH1A1 (0.55) | ALDH1A1NPSR1LMNATDP1KDM4E | |
| SCHEMBL29993792 | 0.73 | ALDH1A1 (0.55) | ALDH1A1NPSR1LMNATDP1KDM4E | |
| SCHEMBL3750754 | 0.73 | NPSR1 (1.00) | ALDH1A1NPSR1MCHR1LMNATP53 | |
| SCHEMBL3755613 | 0.71 | KCNA5 (0.64) | ALDH1A1KCNA5KCNH2 | |
| SCHEMBL3760098 | 0.70 | LMNA (1.00) | ALDH1A1NPSR1MCHR1LMNATP53 | |
| SCHEMBL1618368 | 0.69 | ALDH1A1 (1.00) | ALDH1A1NPSR1MCHR1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | ALDH1A1 315/4885NPSR1 806/4885MCHR1 1915/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | ALDH1A1 310/4885NPSR1 1016/4885MCHR1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.